Pfizer requests EUA for oral COVID-19 antiviral treatment
Pfizer today announced its formal request that the Food and Drug Administration authorize the emergency use of its PAXLOVID (PF-07321332; ritonavir) oral antiviral for combating SARS-CoV-2. Pfizer says data from its phase 2/3 clinical trial shows that the drug, which works as a 3CL protease inhibitor, reduced the risk of COVID-19-related hospitalization or death by 89%.
Related News Articles
Headline
Flu cases are growing or likely growing in 39 states, according to the latest Centers for Disease Control and Prevention data from Nov. 11. COVID-19…
Headline
The Food and Drug Administration yesterday published an announcement from Otsuka ICU Medical saying that the company issued a voluntary recall for a mislabeled…
Headline
A study published Oct. 30 by the American Heart Association found that people have an elevated risk of heart attack and stroke following flu and COVID-19…
Headline
The Centers for Disease Control and Prevention will update its immunization schedules for the COVID-19 and chickenpox vaccines to adopt recent recommendations…
Headline
The Food and Drug Administration today issued a request for public comment on a series of questions regarding current approaches to evaluating artificial…
Headline
The Food and Drug Administration yesterday announced that Olympus issued a global recall of its ViziShot 2 FLEX needles manufactured prior to May 12 following…